{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:19:27Z","timestamp":1771553967308,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Qilu Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40259-023-00579-5","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T21:45:16Z","timestamp":1677015916000},"page":"259-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial"],"prefix":"10.1007","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct04550949","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Huiping","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangcai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runxiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiumei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghong","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuicui","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"issue":"6","key":"579_CR1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s10147-017-1159-1","volume":"22","author":"J Huang","year":"2017","unstructured":"Huang J, Gu T, Ying J. A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer. Int J Clin Oncol. 2017;22(6):1015\u201325. https:\/\/doi.org\/10.1007\/s10147-017-1159-1.","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"579_CR2","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s00520-013-1887-3","volume":"21","author":"G Oster","year":"2013","unstructured":"Oster G, Lamerato L, Glass AG, et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2013;21(12):3279\u201386. https:\/\/doi.org\/10.1007\/s00520-013-1887-3.","journal-title":"Support Care Cancer"},{"issue":"20 Pt 2","key":"579_CR3","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243\u20139.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"579_CR4","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3390\/cells10081978","volume":"10","author":"S Casimiro","year":"2021","unstructured":"Casimiro S, Vilhais G, Gomes I, Costa L. The roadmap of RANKL\/RANK pathway in cancer. Cells. 2021;10(8):1978. https:\/\/doi.org\/10.3390\/cells10081978.","journal-title":"Cells"},{"issue":"4","key":"579_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00520-018-4060-1","volume":"26","author":"A Menshawy","year":"2018","unstructured":"Menshawy A, Mattar O, Abdulkarim A, et al. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2018;26(4):1029\u201338. https:\/\/doi.org\/10.1007\/s00520-018-4060-1.","journal-title":"Support Care Cancer"},{"issue":"35","key":"579_CR6","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body J-J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.29.7101.","journal-title":"J Clin Oncol"},{"issue":"9768","key":"579_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(10)62344-6.","journal-title":"Lancet"},{"issue":"9","key":"579_CR8","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125\u201332. https:\/\/doi.org\/10.1200\/JCO.2010.31.3304.","journal-title":"J Clin Oncol"},{"issue":"3","key":"579_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(18)30072-X.","journal-title":"Lancet Oncol"},{"issue":"12","key":"579_CR10","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1007\/s00520-013-1932-2","volume":"21","author":"R von Moos","year":"2013","unstructured":"von Moos R, Body J-J, Egerdie B, et al. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer. 2013;21(12):3497\u2013507. https:\/\/doi.org\/10.1007\/s00520-013-1932-2.","journal-title":"Support Care Cancer"},{"key":"579_CR11","unstructured":"US Food and Drug Administration. Xgeva (denosumab) label. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125320s201lbl.pdf. [Accessed 15 Jun 2022]."},{"key":"579_CR12","unstructured":"European Medicines Agency. Xgeva (denosumab). Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xgeva. [Accessed 15 Jun 2022]."},{"issue":"3","key":"579_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1152\/physrev.00012.2019","volume":"101","author":"P Cl\u00e9zardin","year":"2021","unstructured":"Cl\u00e9zardin P, Coleman R, Puppo M, et al. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev. 2021;101(3):797\u2013855. https:\/\/doi.org\/10.1152\/physrev.00012.2019.","journal-title":"Physiol Rev"},{"issue":"1","key":"579_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97(1):59\u201369.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"579_CR15","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","volume":"89","author":"JE Brown","year":"2003","unstructured":"Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer. 2003;89(11):2031\u20137.","journal-title":"Br J Cancer"},{"issue":"23","key":"579_CR16","doi-asserted-by":"publisher","first-page":"5713","DOI":"10.1158\/1078-0432.CCR-15-3086","volume":"22","author":"A Lipton","year":"2016","unstructured":"Lipton A, Smith MR, Fizazi K, et al. Changes in bone turnover marker levels and clinical outcomes in patients with advanced cancer and bone metastases treated with bone antiresorptive agents. Clin Cancer Res. 2016;22(23):5713\u201321.","journal-title":"Clin Cancer Res"},{"key":"579_CR17","doi-asserted-by":"publisher","first-page":"100272","DOI":"10.1016\/j.bonr.2020.100272","volume":"12","author":"Z Jiang","year":"2020","unstructured":"Jiang Z, Tang E-T, Li C, et al. What is the relationship between bone turnover markers and skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma? A systematic review and meta-regression analysis. Bone Rep. 2020;12:100272. https:\/\/doi.org\/10.1016\/j.bonr.2020.100272.","journal-title":"Bone Rep."},{"key":"579_CR18","doi-asserted-by":"publisher","first-page":"01329","DOI":"10.3389\/fphar.2020.01329","volume":"11","author":"H Zhang","year":"2020","unstructured":"Zhang H, Wu M, Zhu X, et al. A phase I, randomized, single-dose study to evaluate the biosimilarity of QL1206 to denosumab among Chinese healthy subjects. Front Pharmacol. 2020;11:01329. https:\/\/doi.org\/10.3389\/fphar.2020.01329.","journal-title":"Front Pharmacol"},{"issue":"3","key":"579_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/annonc\/mdh089","volume":"15","author":"SM Ali","year":"2004","unstructured":"Ali SM, Demers LM, Leitzel K, et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol. 2004;15(3):455\u20139.","journal-title":"Ann Oncol"},{"issue":"5","key":"579_CR20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.bone.2012.02.003","volume":"50","author":"R Eastell","year":"2012","unstructured":"Eastell R, Garnero P, Audebert C, Cahall DL. Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study. Bone. 2012;50(5):1141\u20137. https:\/\/doi.org\/10.1016\/j.bone.2012.02.003.","journal-title":"Bone"},{"key":"579_CR21","unstructured":"National Medical Products Administration (NMPA) of China. Statistical guideline of bioequivalence study. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20181029173101911.html. Accessed 9 Jan 2023."},{"key":"579_CR22","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline E9 statistical principles for clinical trials. https:\/\/www.ich.org\/page\/efficacy-guidelines. Accessed 9 Jan 2023."},{"key":"579_CR23","unstructured":"National Medical Products Administration (NMPA) of China. Guideline on biosimilars research & development and evaluation. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20150228155701114.html. Accessed 9 Jan 2023."},{"key":"579_CR24","unstructured":"US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product. Accessed 9 Jan 2023."},{"key":"579_CR25","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. https:\/\/www.ema.europa.eu\/en\/similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical-clinical-issues. Accessed 9 Jan 2023."},{"issue":"15_Suupl.","key":"579_CR26","doi-asserted-by":"publisher","first-page":"10116","DOI":"10.1200\/JCO.2016.34.15_suppl.10116","volume":"34","author":"Z Jiang","year":"2016","unstructured":"Jiang Z, Shao Z, Zhang Q, et al. Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors. J Clin Oncol. 2016;34(15_Suupl.):10116. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.10116.","journal-title":"J Clin Oncol"},{"issue":"11","key":"579_CR27","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/pds.4045","volume":"25","author":"ALH Huynh","year":"2016","unstructured":"Huynh ALH, Baker ST, Stewardson AJ, Johnson DF. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf. 2016;25(11):1274\u20138. https:\/\/doi.org\/10.1002\/pds.4045.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"579_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40264-019-00888-1","volume":"43","author":"E Megapanou","year":"2020","unstructured":"Megapanou E, Florentin M, Milionis H, Elisaf M, Liamis G. Drug-induced hypophosphatemia: current insights. Drug Saf. 2020;43(3):197\u2013210. https:\/\/doi.org\/10.1007\/s40264-019-00888-1.","journal-title":"Drug Saf"},{"issue":"4","key":"579_CR29","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734\u201355. https:\/\/doi.org\/10.1002\/cpt.1836.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"579_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4155\/bio.14.311","volume":"7","author":"PM Liu","year":"2015","unstructured":"Liu PM, Zou L, Sadhu C, Shen WD, Nock S. Comparative immunogenicity assessment: a critical consideration for biosimilar development. Bioanalysis. 2015;7(3):373\u201381. https:\/\/doi.org\/10.4155\/bio.14.311.","journal-title":"Bioanalysis"},{"key":"579_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bone.2019.04.022","volume":"125","author":"J Mart\u00ednez-Reina","year":"2019","unstructured":"Mart\u00ednez-Reina J, Pivonka P. Effects of long-term treatment of denosumab on bone mineral density: insights from an in-silico model of bone mineralization. Bone. 2019;125:87\u201395. https:\/\/doi.org\/10.1016\/j.bone.2019.04.022.","journal-title":"Bone"},{"issue":"4","key":"579_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2165\/11598090-000000000-00000","volume":"51","author":"L Gibiansky","year":"2012","unstructured":"Gibiansky L, Sutjandra L, Doshi S, et al. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet. 2012;51(4):247\u201360. https:\/\/doi.org\/10.2165\/11598090-000000000-00000.","journal-title":"Clin Pharmacokinet"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00579-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00579-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00579-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T13:40:05Z","timestamp":1677505205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00579-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00579-5","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]},"assertion":[{"value":"11 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Qilu Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Cuicui Han, Yunjie Li, and Xiaoyan Kang are employees of Qilu Pharmaceutical Co., Ltd. All the other authors have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The study protocol was approved by the ethics committee in each center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent before participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available because we may further analyze the raw data for other research objectives.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"HL and\u00a0LZ had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: HL, YH, CH, XK, LZ. Acquisition, analysis, or interpretation of data: all authors. Drafting of the manuscript: HL, YH, LZ. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: YL. Obtained funding: HL,\u00a0XK, LZ. Administrative, technical, or material support: CH, XK. Supervision: HL,\u00a0XK, LZ.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}